The Fondation Maladies Rares is pleased to announce the launch of its “GenOmics” 2024 call for projects.
The aim of this AAP is to support hypothesis-driven research projects aimed at exploring the genetic and molecular basis of rare diseases using NGS approaches (WES, WGS, RNA-seq, small RNA-seq, ChIP-seq, Methyl-seq, etc.).
Support from the Fondation Maladies Rares will give project leaders access to innovative high-throughput sequencing technologies for the analysis of exomes, genomes, transcriptomes or epigenomes.View this resource Bookmark this resource
The Fondation Maladies Rares and UCB have joined forces to offer a €30, 000 research grant to a humanities and social sciences (HSS) research project focused on findingconcrete, short-term ways ofimproving the life course of patients suffering from generalized autoimmune myasthenia gravis.
The grant will be awarded to a research project focusing on the individual, family and/or social consequences specifically linked to generalized autoimmune myasthenia gravis, in order to gain a better understanding of the impact of this disease, and in particular muscular fatigability, on quality of life at the level of the individual, couple or family, for example.View this resource Bookmark this resource
The purpose of this funding opportunity announcement (FOA) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs. Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development.View this resource Bookmark this resource
NCATS seeks to facilitate rare diseases research by enabling efficient and effective movement toward clinical trials in multiple rare diseases. The purpose of this NOFO is to provide support for basket clinical trials of drugs targeting shared molecular etiologies in more than one rare disease, and in the process to identify and overcome challenges in adapting the oncology basket trial model to rare diseases. Projects proposed for this NOFO will require individuals with expertise in carrying out clinical trials in rare diseases. Applicants are expected to collaborate with clinical investigators at academic institutions. Projects involving clinical investigators who are part of the Rare Disease Clinical Research Network (RDCRN) and which focus on diseases under study in the RDCRN are strongly encouraged. See https://www.rarediseasesnetwork.org/ for additional information.View this resource Bookmark this resource
The purpose of this funding opportunity announcement (FOA) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions. Additionally, through the funding of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare diseases and exert a broad and positive impact on rare disease drug development.View this resource Bookmark this resource
This Notice of Funding Opportunity (NOFO) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics toward clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.View this resource Bookmark this resource
This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning.View this resource Bookmark this resource
The purpose of this funding opportunity announcement (FOA) is to support efficient natural history studies alone or in conjunction with the development and validation of clinical outcome assessments (COAs) and/or biomarker studies to address the unmet needs in rare neurodegenerative diseases for children and adults. Through the support of studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare neurodegenerative disease or multiple rare neurodegenerative diseases with similar pathophysiology, and facilitate rare disease product development.View this resource Bookmark this resource
This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS expects to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.View this resource Bookmark this resource